The latest price target for Compass Therapeutics (NASDAQ:CMPX) was reported by Guggenheim on March 24, 2026. The analyst firm set a price target for $12.00 expecting CMPX to rise to within 12 months (a possible 122.22% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Compass Therapeutics (NASDAQ:CMPX) was provided by Guggenheim, and Compass Therapeutics reiterated their buy rating.

The last upgrade for Compass Therapeutics Inc happened on April 2, 2025 when Leerink Partners raised their price target to $6. Leerink Partners previously had a market perform for Compass Therapeutics Inc.

There is no last downgrade for Compass Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compass Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compass Therapeutics was filed on March 24, 2026 so you should expect the next rating to be made available sometime around March 24, 2027.

While ratings are subjective and will change, the latest Compass Therapeutics (CMPX) rating was a reiterated with a price target of $12.00 to $12.00. The current price Compass Therapeutics (CMPX) is trading at is $5.40, which is out of the analyst’s predicted range.